How LIR Life Sciences is making GLP-1 therapy easier to access worldwide
This content was created by Hive Labs in partnership with Fairfax Partners on behalf of LIR Life Sciences Corp. Treating obesity isn’t always as simple as telling someone to lose weight, and with the World Obesity Federation estimating that nearly four billion people worldwide will be affected by overweight and obesity by 2035, the need […]
STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data
The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy that would require all hospitals that participate in a federal drug discount program to submit comprehensive claims data, the first time that a large pharmaceutical company has taken such a step. The new Lilly policy, which is […]
The 5 Worst Things You Can Do While Taking a GLP-1 for Weight Loss
According to doctors, making a misstep is easier than you may think.
Endocrinologist-Designed AI Nutrition App Launches to Bring Clarity to Eating in the GLP-1 Era
Developed by board-certified endocrinologist Dr. Eiriny Eskander, Caloria delivers physician-backed insights for people managing GLP-1 use, diabetes, PCOS, and menopause. LOS ANGELES, Jan. 26, 2026 /PRNewswire/ — At a time when millions of people are turning to GLP-1 medications and…
Data Shows GLP-1 Drugs Subtly Shift Cravings Toward Real Food
Post Content
SGLT2 Inhibitors Linked to Lower Neuropathy Risk
Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those taking GLP-1 receptor agonists. Medscape Medical News
Ozempic boom collides with America’s eating habits as restaurants shrink portions
Once known for bottomless breadsticks and supersized meals, American chain restaurants are increasingly rethinking their portion sizes. As GLP-1 weight-loss medications like Ozempic, Wegovy and Zepbound go mainstream, restaurants are responding to customers with smaller appetites — and a growing appetite for protein-packed meals. “People on GLP-1s are prioritizing protein because it’s the macronutrient that […]
STAT+: Launch of Wegovy pill looks to be going strong so far
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we see a new synthetic biology startup, backed by Frances Arnold and Bob Langer. Plus, it’s still early, but Novo Nordisk already appears to be having a robust rollout of the Wegovy pill. […]
GLP‐1RAs versus metformin and Parkinson’s risk in type 2 diabetes
Abstract Background Parkinson’s disease (PD) is an increasingly prevalent neurodegenerative condition, particularly among individuals with type 2 diabetes mellitus (T2DM). While prior studies have suggested that GLP-1 receptor agonists (GLP-1RAs) and metformin may confer neuroprotective effects, most were limited by small sample sizes, short follow-up, uncontrolled designs, or lacked direct comparisons between therapies—making their findings […]
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant milestone in the development of its obesity drug VK2735. Data published in the peer-reviewed journal Obesity show that the drug achieved a weight loss of 14.7% from baseline after 13 […]